In this context it has been suggested that epigenetic inhibitors could be useful to revert this HCV-induced epigenetic signature as well as the EGFR inhibitor erlotinib, for the involvement of the EGFR in the induction of the epigenetic changes following the infection. This evidence concerns the gene EGFR and infection.